免疫疗法如Pembrolizumab（PEM）在许多癌症类型的治疗中越来越普遍。PEM通过增强T细胞抗肿瘤反应的方式已有大量文献报道。然而，PEM对其他免疫细胞在促进肿瘤退缩和清除方面的相互作用尚不明确，需要进一步研究。本综述提供了文献报道PEM与刺激先天免疫细胞和适应性免疫细胞相互作用的发现，这种相互作用增强了细胞毒性表型，并触发细胞因子和趋化因子的分泌，对人体有益和有害的效应都存在。我们还描述了这如何导致PEM诱发少见但未充分报道的免疫相关心血管并发症的快速发展和致残并致命后果。本综述鼓励进一步研究PEM诱发的心血管并发症，以及癌症患者中其他免疫细胞的相互作用。随着PEM疗法在癌症治疗中的扩大应用，我们期望本综述能够告知皮肤科（黑色素瘤皮肤癌）、眼科（眼部肿瘤）和病理学（血液恶性肿瘤）等不同医学专科的医疗专家有关PEM导致的心脏并发症的信息。

The use of immunotherapies like Pembrolizumab (PEM), is increasingly common for the management of numerous cancer types. The use of PEM to bolster T-cell response against tumor growth is well documented. However, the interactions PEM has on other immune cells to facilitate tumor regression and clearance is unknown and warrants further investigation. In this review, we present literature findings that have reported the interactions of PEM in stimulating innate and adaptive immune cells, which enhance cytotoxic phenotypes. This triggers secretion of cytokines and chemokines, which have both beneficial and detrimental effects. We also describe how this leads to the development of rare but under-reported occurrence of PEM-induced immune-related cardiovascular complications that arise suddenly and progress rapidly to debilitating and fatal consequences. This review encourages further research and investigation of PEM-induced cardiovascular complications, and other immune cell interactions in cancer patients. As PEM therapy in treating cancer types is expanding, we expect that this review will inform health care professionals of diverse specializations of medicine like dermatology (melanoma skin cancers), ophthalmology (eye cancers), and pathology (hematological malignancies) about PEM-induced cardiac complications.